Lv2
128 积分 2024-10-25 加入
Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Compared with Chemotherapy as First-Line Treatment for Advanced PD-L1-Positive Triple-Negative Breast Cancer from a Japanese Healthcare Perspective
3个月前
已完结
Is Alpelisib Plus Fulvestrant Cost-Effective for Treating PIK3CA-Mutation, HR+/HER2− Advanced Breast Cancer in the USA?
3个月前
已完结
The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2− Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered
3个月前
已完结
Abbreviations
6个月前
已完结
Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China
7个月前
已完结
Cost-effectiveness of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a comparative analysis in China, the United States and Europe
7个月前
已关闭
Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States
7个月前
已完结
Cost–Effectiveness Analysis of Nivolumab Plus Cabozantinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma
7个月前
已完结
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States
7个月前
已完结
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
7个月前
已完结
皖公网安备34019202002308
